BNTX Apr 2024 155.000 put
| Previous close | 51.70 |
| Open | 51.70 |
| Bid | 46.00 |
| Ask | 49.40 |
| Strike | 155.00 |
| Expiry date | 2024-04-19 |
| Day's range | 51.70 - 51.70 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Globe NewswireThree-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”)A randomized Phase 2 clinical trial with autogene cevumeran in patients with resected PDAC is currently enrolling patients at clinical trial sites in the United States, with addit
Barrons.comThis Vaccine Maker Sits on Cash Almost Equal to Its Market Value
This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.
- Reuters
UPDATE 2-BioNTech gets US agency notice over default on COVID vaccine royalties
BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comment.
